EpitoGen Technology and AiBiologics machine learning software (EpitopePredikt) were employed to develop a set of unique, highly sensitive SARS-Cov-2 ELISA assays. EpitopePredikt was used to scan SARS-CoV-2 antigen and identify immunodominant epitopes. The epitopes were then expressed in combination using EpitoGen Technology and validated for detection of [...]

EpitoGen Technology is a novel epitope/peptide expression platform. The epitope antigen (Epitogen) is fused in the middle of an inert scaffold protein and displayed on the top of the scaffold ideally suited to a number of antigen/antibody-based assays such as ELISA and lateral flow. The technology was [...]

Vertebrate Antibodies will utilise its proprietary AI and recombinant technologies to tackle Covid-19Vertebrate Antibodies Ltd (VAL) is joining forces with leading scientists and clinicians from University of Aberdeen and NHS Grampian.Existing tests can be unreliable and are not suited to rapid and mass deployment. This project, funded by [...]

4th October 2019 VAL is pleased to confirm the appointment of Richard Atkins as Director of Commercialisation. He will lead the marketing and business development of VAL’s projects. About Richard Atkins For over 30 years Richard has become very commercially driven with significant strategic, communication and growth [...]

1st October 2019 VAL is pleased to confirm the appointment of Dr Tiehui Wang as Director of Biologicals. He will be the head of the Recombinat Division and generate active proteins for research and animal health. About Dr Tiehui Wang Dr Tiehui Wang is a leading immunologist [...]